The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
New Phase II data show vast majority of patients experiencing no relapses or disability progression
The Unit has been issued GMP Certification from ANVISA-Brazil
Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer and GSK will continue to vigorously defend itself against all claims
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
_256_384.png)
Global Phase-3 study initiation expected in the second half of 2024
_256_384.jpg)
This facility manufactures APIs & formulations of oncology and non-oncology products.
A five-day inspection was concluded successfully with no critical and no major observations raised
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
